The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
|Articles|September 16, 2008
- July31 2003
- Volume 10
- Issue 14
CAR INSURANCE SHOPPING
Author(s)Michael Sheehan
Advertisement
Auto insurance rates are on therise, which makes it more importantthan ever to shop around. Eachinsurer has its own way of blendingrisk factors (eg, age, location, anddriving record) to come up with apremium, which means that policiescan vary widely in price. A recentsurvey by Progressive Corp showsthat premiums on the same 6-month policy differ by an average of$586—almost $100 a month. Startyour shopping at a Web site likeInsure.com and then contact individualcompanies. Don't forget to mentionitems that can lower your rate(eg, airbags, antilock brakes, passengerrestraints, and antitheft devices).
Articles in this issue
about 18 years ago
"The Horses Are at the Starting Gate"about 18 years ago
IRS EYES LEASINGabout 18 years ago
DOCTORS ONLINEabout 18 years ago
CREDIT CARD HOMEabout 18 years ago
RETIRE IN A HEALTHY STATEabout 18 years ago
TRUSTS & MOREabout 18 years ago
DID YOU KNOW?about 18 years ago
PRN: Harness Human Nature's Quirksabout 18 years ago
WHAT PRIVILEGE?about 18 years ago
BEFORE YOU MARRYAdvertisement
Related to this article
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.
Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
Long-term extension data show iptacopan held a −3.49 mL/min/1.73 m² per year eGFR slope over 48 months, with benefit emerging after patients switched from placebo.
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Kidney Compass: ORIGIN 3 Final eGFR Data for Atacicept in IgA Nephropathy
3
Sibeprenlimab Stabilizes eGFR Over 24 Months in IgA Nephropathy: VISIONARY
4
Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes
5